Recently, the net worth changes in quantitative private equity last week were gradually updated, and retracements of -10% or more abound. Many products not only fell below -20% in July, but excess returns within 2026 were also declared negative. Magic Square Quantification, Jiukun Investment, Mingyi Investment, and Derivative Investment, known as the “Big Four Kings” of quantification, were not spared. The net worth of many of its products retraced more than 10% last week. Take Liang Wenfeng's Magic Square Quantization as an example. According to data from the Private Equity Ranking Network, the net value of the company's China Securities 500 quantitative products, the Shanghai and Shenzhen 300 quantitative multi-strategy, and the China Securities 1000 quantitative multi-strategy, fell by more than 15% last week. Among them, the net worth of the Magic Square Quantitative Xinhuai 500 Index exclusive No. 19 Phase 7 fell 15.82% last week. According to data from the Private Equity Ranking Network, the product's excess revenue in July this year was -10.85%.

Recently, the net worth changes in quantitative private equity last week were gradually updated, and retracements of -10% or more abound. Many products not only fell below -20% in July, but excess returns within 2026 were also declared negative. Magic Square Quantification, Jiukun Investment, Mingyi Investment, and Derivative Investment, known as the “Big Four Kings” of quantification, were not spared. The net worth of many of its products retraced more than 10% last week. Take Liang Wenfeng's Magic Square Quantization as an example. According to data from the Private Equity Ranking Network, the net value of the company's China Securities 500 quantitative products, the Shanghai and Shenzhen 300 quantitative multi-strategy, and the China Securities 1000 quantitative multi-strategy, fell by more than 15% last week. Among them, the net worth of the Magic Square Quantitative Xinhuai 500 Index exclusive No. 19 Phase 7 fell 15.82% last week. According to data from the Private Equity Ranking Network, the product's excess revenue in July this year was -10.85%.